Facing a shortage, GLP-1 weight loss drugs by Eli Lilly & Novo Nordisk struggle to meet demand. Learn about supply issues and efforts to address them, impacting availability till 2025.
The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says that? The companies that make those drugs predict. The weight loss drug frenzy took off when the FDA approved Novo Nordisk A/S’s (NYSE:NVO) Wegvoy (semaglutide) in 2021. Eli Lilly And Co’s (NYSE:LLY) Zepbound (tirzepatide) appears to spur the momentum after receiving FDA approval in November 2023. According to the FDA, limited supplies of Eli Lilly’s d